Weight gain during treatment course of allogenic hematopoietic stem cell transplantation in patients with hematological malignancies affects treatment outcome

Cytotherapy. 2022 Dec;24(12):1190-1194. doi: 10.1016/j.jcyt.2022.08.006. Epub 2022 Sep 20.

Abstract

Background aims: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an effective treatment for patients with hematological malignancies; however, allo-HSCT does not come without the cost of treatment-related morbidity and mortality. Early detection of risk factors could be helpful in identifying patients who could benefit from early interventions. Many patients gain weight during the allo-HSCT treatment, although little is known about the impact of weight gain.

Methods: Weight gain in 146 consecutively enrolled adult patients undergoing allo-HSCT was explored.

Results: In total, 141 patients (97%) gained weight along the course of allo-HSCT. Median weight increase was 4.8 kg (range 0.0-16.1 kg), with median increase in body weight 6.5% (range 0.0%-30.8%). Maximum weight increase was observed at day +7 (range day -8, +44). Weight gain was associated with increased incidence of acute graft-versus-host disease. Patients with weight gain >10% had a significantly greater 5-year mortality compared with those with lower weight gain (P = 0.031, rank sum test).

Conclusions: Weight gain is a simple variable with the ability to provide prognostic information for patients undergoing allo-HSCT.

Keywords: Allogeneic stem cell transplantation; Capillary leak syndrome; Graft versus host disease; Weight increase.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Graft vs Host Disease* / etiology
  • Graft vs Host Disease* / therapy
  • Hematologic Neoplasms* / complications
  • Hematologic Neoplasms* / therapy
  • Hematopoietic Stem Cell Transplantation* / adverse effects
  • Humans
  • Retrospective Studies
  • Transplantation, Homologous / adverse effects
  • Treatment Outcome
  • Weight Gain